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Introduction
The ﬁrst line of treatment for type 2 diabetes usually
involves lifestyle changes including diet and exercise
(1) as well as oral antidiabetic drugs (OADs). How-
ever, as a result of the progressive nature of the
disease, many patients require insulin therapy to
control their blood glucose levels effectively (2,3) and
minimise the risk of long-term complications. It is
therefore important to initiate insulin therapy early
in the disease process (4–6). The simplest and often
popular way of initiating insulin is to start with basal
insulin therapy (7). Basal insulin therapy, with or
without OADs, can be an effective treatment option
with just one daily injection and this simple regimen
allows patients to adjust to a major change in the
management of their diabetes.
Modern basal insulin analogues are effective in
reducing HbA1c and have also shown an improved
safety proﬁle compared with human insulins (8).
However, insulin titration, or even changing the type
of insulin, may be critical for the achievement of
adequate glycaemic control (9). While basal insulin
may be a good option for starting insulin treatment
in some patients, patients’ needs change over time
and glycaemic control (especially after meals) may
become inadequate with basal only therapy (10); at
this point the therapy should be intensiﬁed to either
SUMMARY
Aims: The international IMPROVE
TM
observational study investigated the safety
proﬁle and effectiveness of biphasic insulin aspart 30⁄70 (BIAsp 30) in the routine
treatment of patients with type 2 diabetes. We present analyses for the subgroup
of patients who switched from basal insulin to BIAsp 30. Methods: Patients in
routine care who started insulin therapy with or switched to BIAsp 30 from exist-
ing insulin regimens were eligible for this 26-week study. This analysis includes
only patients previously treated with basal insulin. Outcomes including adverse
events, hypoglycaemic events and glycaemic proﬁle were recorded from patients’
notes, recall and diaries. Results: Of the 748 patients included (age
59.7 ± 11.8 years, diabetes duration 11.4 ± 7.3 years, baseline HbA1c 9.1 ±
1.6%), 497 were previously using human neutral protamine Hagedorn (NPH) insu-
lin and 245 analogue basal insulin. Overall, major and minor hypoglycaemia rates
decreased from baseline to ﬁnal visit (major: 0.171 to 0.011; minor: 9.70 to 5.89
events⁄patient-year) and were similar between the subgroups. HbA1c and fasting
blood glucose were signiﬁcantly reduced from baseline (NPH prestudy: )1.6%,
)2.4 mmol⁄l; analogue basal prestudy: )1.8%, )2.4 mmol⁄l), as was postpran-
dial blood glucose, with 33.8% of patients achieving the HbA1c target < 7% with-
out hypoglycaemia. Insulin dose increased slightly from prestudy (0.33 ±
0.21 U⁄kg), baseline (0.40 ± 0.20 U⁄kg) to ﬁnal visit (0.52 ± 0.26 U⁄kg); most
patients (76%) followed a twice-daily regimen at ﬁnal visit. Body weight did not
change signiﬁcantly and treatment satisfaction increased. Conclusions: Patients
with type 2 diabetes inadequately controlled on basal insulins may improve their
glycaemic control by intensiﬁcation to BIAsp 30 therapy.
What’s known
Intensiﬁcation from basal insulin regimen to
biphasic insulin aspart 30 ⁄ 70 (BIAsp 30) can result
in improved glycaemic control in patients with type
2 diabetes as BIAsp 30 covers both basal and
prandial insulin needs.
What’s new
• Here, we present results from a subgroup of
inadequately controlled patients previously
treated with basal insulins who intensiﬁed their
therapy to BIAsp 30 and improved their
glycaemic control, in many cases without
hypoglycaemia.
• Patients were more satisﬁed with BIAsp 30
treatment than with their previous regimen.
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966 doi: 10.1111/j.1742-1241.2009.02064.xa basal–bolus or a premixed insulin regimen. Pre-
mixed insulin analogues offer the advantage of fewer
daily injections than basal–bolus regimens as they
provide both intermediate and rapid-acting compo-
nents for basal and prandial insulin needs (11).
Biphasic insulin aspart 30⁄70 (BIAsp 30) is a pre-
mixed insulin analogue containing 30% soluble,
rapid-acting insulin aspart and 70% intermediate-
acting protamine-bound aspart in each injection.
Several clinical trials have shown that initiating with
or switching to BIAsp 30 therapy can achieve better
glycaemic control than basal insulin therapy (9,12–
15).
In addition, data from observational studies in
diabetes provide valuable information as they com-
plement results from randomised controlled trials
(RCTs) and can indicate whether the beneﬁts associ-
ated with particular treatments in RCTs translate
into ‘real-life’ clinical practice (16,17). Results of one
such observational study (PRESENT) have suggested
that when patients are failing to reach glycaemic tar-
gets using basal insulin, they can improve their gly-
caemic control by intensifying their therapy to BIAsp
30 (18).
The IMPROVE
TM study is a multinational obser-
vational study – the largest dataset to date – investi-
gating the safety proﬁle and effectiveness of BIAsp 30
in the treatment of type 2 diabetes (19). Here, we
analysed safety and effectiveness results of BIAsp 30
treatment in patients who used basal insulin regi-
mens before enrolling in the study and intensifying
to BIAsp 30.
Methods
Study design
IMPROVE
TM is a 26-week, open-label, non-rando-
mised, multicentre observational study of patients
with type 2 diabetes conducted in 11 countries (Can-
ada, China, Greece, Gulf region, India, Iran, Italy,
Japan, Poland, Russia and South Korea). Any patient
with type 2 diabetes prescribed BIAsp 30 in routine
clinical practice was eligible for the study. The details
of the of IMPROVE
TM study design have been pub-
lished elsewhere (19).
In this paper, we report results of a subgroup of
patients previously treated with basal insulins
(human or analogue) with or without OADs. BIAsp
30 was prescribed as part of routine care once (qd),
twice (bid) or three times daily (tid) depending on
the patient’s needs. The dose and timing of BIAsp 30
treatment and of any concomitant medication were
at the discretion of the physician. The dose was
adjusted individually and any changes in BIAsp 30
treatment were recorded at the follow-up visit (at
3 months) and the ﬁnal visit (at 26 weeks). The
study was conducted in accordance with the Declara-
tion of Helsinki. Procedures complied with local reg-
ulations governing observational studies, which were
applicable to health authority and ethics committee
approval and patient informed consent. Physicians
received remuneration according to local regulations
for the time spent collecting patient data.
Outcome measures
The primary outcome measure was the incidence of
major hypoglycaemic events reported as serious
adverse drug reactions (SADRs). The secondary out-
come measures included SADRs, number of major
and minor hypoglycaemic events, changes in weight
and body mass index (BMI), HbA1c, proportions of
patients reaching a target of HbA1c < 7.0%, fasting
blood glucose (FBG), postprandial blood glucose
(PPBG) after all main meals and treatment satisfac-
tion as measured by the Diabetes Medication Satis-
faction (DiabMedSat) questionnaire (20).
The full analysis set (FAS) included all patients
with a baseline visit and at least one BIAsp 30 dose.
The efﬁcacy analysis set was deﬁned as above but
with at least one measurement of a hypoglycaemic
event, blood glucose, weight or HbA1c at baseline
and ﬁnal visit. Major hypoglycaemia was deﬁned as
an event with severe central nervous system symp-
toms that could not be self-treated, with either blood
glucose levels < 2.8 mmol⁄l or symptoms that were
reversed with either carbohydrate intake or glucagon
or intravenous glucose administration. Minor hypo-
glycaemic events were deﬁned as either symptoms of
hypoglycaemia with blood glucose levels < 2.8 mmol⁄l
that could be self-treated, or any asymptomatic blood
glucose measurement < 2.8 mmol⁄l (19). Major
hypoglycaemic events were recorded over 13 weeks
prior to each visit and minor hypoglycaemic events
over 4 weeks prior to each visit; both were then
calculated as events per patient-year.
Statistical analyses
Statistical comparisons of BIAsp 30 outcome mea-
sures at baseline and ﬁnal visit were performed with
paired t-tests for continuous variables and with Wil-
coxon signed-rank tests for discrete variables. All
testing used two-sided tests with the criteria set at
a = 0.05.
Results
Patients
A summary of patient demographics is shown in
Table 1. Of the total 748 patients included, 66.4%
were using human neutral protamine Hagedorn
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glargine ± OADs (n = 157) and 11.8% insulin det-
emir ± OADs (n = 88). Six patients (0.8%) were
using other basal insulins or combinations (NPH
plus glargine or detemir) and were excluded from
the analysis, as they did not ﬁt the predeﬁned
groups. The majority of patients (87%) were using
one or more OADs before the baseline visit.
Safety
Of the 748 patients included in the safety analysis
(FAS with ﬁnal visit), only one patient (0.13%)
reported a hypoglycaemic event as an SADR during
the study. The proportion of patients reporting
major hypoglycaemic events declined from 2.4% at
baseline to 0.3% after 26 weeks and fewer patients
reported minor hypoglycaemic events at the end of
the study (17%) compared with baseline (27%).
Hypoglycaemia rates and reductions were very
similar for patients coming from human or analogue
basal prestudy therapy (Figure 1).
Effectiveness
All measures of glycaemic control – HbA1c, FBG and
PPBG concentrations following breakfast, lunch and
dinner – signiﬁcantly improved after 26 weeks of
BIAsp 30 treatment (p < 0.001) (Table 2). The mean
HbA1c reduction was 1.7%, FBG reduction was
2.35 mmol⁄l and PPBG reduction after breakfast was
4.36 mmol⁄l over the study period. Furthermore,
39.0% of patients achieved the HbA1c targets of
< 7%. The patients who achieved this target without
hypoglycaemia (n = 253; 33.8%) had lower HbA1c at
baseline (8.58 ± 1.65%) and ﬁnal visit (6.40 ±
0.40%) (change )2.17 ± 1.69%) compared with the
total group. The changes in glycaemic measures were
similar for patients switching from both human and
analogue basal insulins (Table 2). What is more,
Table 1 Patient demographics
Demographic
Prestudy therapy
All patients using basal insulin (n = 748) Human insulin (n = 497)* Analogue insulin (n = 245)*
Age (years) 59.7 ± 11.8 60.5 ± 11.7 58.0 ± 11.9
Gender, M⁄F (%) 48⁄52 44⁄56 56⁄44
Weight (kg) 80.8 ± 19.6 81.2 ± 19.7 80.2 ± 19.3
BMI (kg⁄m
2) 29.7 ± 6.9 30.0 ± 7.1 29.3 ± 6.4
Duration of diabetes (years) 11.4 ± 7.3 11.4 ± 7.0 11.4 ± 7.9
HbA1c (%) 9.1 ± 1.6 9.0 ± 1.5 9.3 ± 1.8
Patients with⁄without OADs prestudy (%) 86.9⁄13.1 87.1⁄12.9 87.8⁄12.2
Data are mean (±SD) unless stated otherwise. *Six patients had other combinations of insulin and were excluded from the analyses. BMI, body mass index; OADs,
oral antidiabetic drugs.
Figure 1 Rates of major and minor hypoglycaemia at baseline and ﬁnal visit, according to prestudy basal insulin therapy
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similar mean HbA1c reduction after switching to
BIAsp 30 to those in the bid prestudy basal insulin
group ()1.70%, )1.57% respectively).
Weight
There was no signiﬁcant weight change from baseline
(80.77 ± 19.6 kg) to ﬁnal visit (80.74 ± 19.2 kg;
change )0.03 ± 4.4 kg) and BMI was also stable
(29.69 kg⁄m
2 at both baseline and ﬁnal visit).
Patients switching from both human and analogue
basal insulins showed similar results (Table 2).
BIAsp 30 dose and injection frequency
The mean total insulin daily dose increased from
prestudy (0.33 ± 0.21 U⁄kg), baseline (0.40 ±
0.20 U⁄kg) to ﬁnal visit (0.53 ± 0.26 U⁄kg). Patients
using qd basal insulin prestudy (n = 437) started on
a slightly lower dose than those using bid basal insu-
lins (n = 289) (0.36 vs. 0.44 U⁄kg respectively).
However, the BIAsp 30 dose increased similarly in
both cases by the end of the study (0.50 vs.
0.57 U⁄kg; dose change 0.14 vs. 0.13 U⁄kg respec-
tively). For patients who achieved an HbA1c target of
< 7% without hypoglycaemia, the mean total BIAsp
30 daily dose increased from 0.37 ± 0.18 U⁄kg at
baseline to 0.46 ± 0.22 U⁄kg at ﬁnal visit.
Prior to the study, 58.4% of patients were using a
qd basal insulin regimen (n = 437); 38.6% (n = 289)
a bid regimen; 1.7% (n = 13) used insulin tid and
1.2% (n = 9) injected insulin four times per day. At
baseline, the majority of patients started using BIAsp
30 bid (n = 612, 81.8%); 12.0% (n = 90) used BIAsp
30 qd and 6.1% (n = 46) injected BIAsp tid. By the
end of the study, 75.8% of patients (n = 567) were
still using BIAsp 30 bid, a qd BIAsp 30 regimen was
Table 2 Change from baseline in effectiveness parameters when using BIAsp 30 for 6 months
Outcome measure
Prestudy therapy
All patients using basal insulin (n = 748) Human insulin (n = 497) Analogue insulin (n = 245)
HbA1c (%)
Baseline 9.11 ± 1.63 8.97 ± 1.48 9.31 ± 1.80
Final visit 7.39 ± 1.16 7.34 ± 1.06 7.48 ± 1.32
Change from baseline )1.72 ± 1.58*** )1.64 ± 1.44*** )1.83 ± 1.72***
Patients reaching
HbA1c < 7.0% (%) 39 40.7 34.8
FBG (mmol⁄l)
Baseline 9.45 ± 2.51 9.54 ± 2.43 9.32 ± 2.65
Final visit 7.10 ± 1.99 7.18 ± 2.13 6.94 ± 1.69
Change from baseline )2.35 ± 2.97*** )2.36 ± 3.00*** )2.38 ± 2.92***
PPBG breakfast (mmol⁄l)
Baseline 12.88 ± 3.69 12.56 ± 3.54 13.59 ± 3.89
Final visit 8.51 ± 2.17 8.28 ± 2.15 8.98 ± 2.17
Change from baseline )4.36 ± 3.30*** )4.28 ± 3.23*** )4.60 ± 3.42***
PPBG lunch (mmol⁄l)
Baseline 11.94 ± 3.36 11.65 ± 3.15 12.57 ± 3.69
Final visit 8.35 ± 1.61 8.14 ± 1.38 8.78 ± 1.93
Change from baseline )3.59 ± 3.30*** )3.52 ± 3.12*** )3.79 ± 3.64***
PPBG dinner (mmol⁄l)
Baseline 11.64 ± 2.75 11.61 ± 2.72 11.68 ± 2.79
Final visit 8.20 ± 1.94 8.06 ± 1.64 8.63 ± 2.64
Change from baseline )3.44 ± 2.82*** )3.55 ± 2.70*** )3.06 ± 3.11***
BIAsp 30 daily dose (U⁄kg)
Baseline 0.40 ± 0.20 0.39 ± 0.20 0.40 ± 0.20
Final visit 0.53 ± 0.26 0.54 ± 0.25 0.50 ± 0.27
Change from baseline 0.13 ± 0.20*** 0.14 ± 0.20*** 0.10 ± 0.20***
Weight (kg)
Baseline 80.77 ± 19.63 81.16 ± 19.69 80.21 ± 19.34
Final visit 80.74 ± 19.24 81.26 ± 19.38 79.91 ± 18.78
Change from baseline )0.03 ± 4.38 ns )0.10 ± 3.49 ns )0.30 ± 5.82 ns
Values are mean (± SD). ***p < 0.0001; ns, not signiﬁcant; FBG, fasting blood glucose; PPBG, postprandial blood glucose; BIAsp 30, biphasic insulin aspart 30⁄70.
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by 17.8% of patients (n = 133). At the ﬁnal visit,
62% of patients were still using one or more OADs.
Patient satisfaction
At baseline, only 12.2% of patients were very or
extremely satisﬁed with their current diabetes treat-
ment; at ﬁnal visit this proportion increased to
59.7%. The corresponding proportions for those
switching from human and analogue basal insulins
were 11.6 to 61.0% and 13.6 to 55.4% respectively.
Discussion
The results of this subgroup analysis of the IMPRO-
VE
TM study suggest that by intensifying basal insulin
regimens to a BIAsp 30 regimen in routine care, gly-
caemic control can be signiﬁcantly improved in inad-
equately controlled patients with type 2 diabetes.
Furthermore, the improved glycaemic control was
achieved with a reduced risk of both major and
minor hypoglycaemic events and with no signiﬁcant
change in weight. All these factors contributed to the
increased patient treatment satisfaction following a
switch from basal insulin to BIAsp 30. The Diab-
MedSat questionnaire, which was used to assess
treatment satisfaction, is a tool which integrates mea-
sures for disease burden, symptom relief, treatment
burden and medication satisfaction (20). The greater
overall satisfaction with diabetes medication that we
report for BIAsp 30 compared with the previous
insulin therapy is thus a clear indication of improve-
ments in many aspects of patients’ lives.
The improvement seen in this cohort with poor
glycaemic control at baseline indicates that a more
intensive insulin therapy is not only appropriate, but
long overdue. These patients previously using basal
insulin (almost 90% were also taking OADs) had been
diagnosed, on average, over 11 years previously and
had mean HbA1c levels above 9%. Long-term hyper-
glycaemia will bring an increased risk of diabetic com-
plications (2), so further intervention was certainly
required in these patients. Basal insulins can be effec-
tive when glycaemic control is particularly poor, but
their beneﬁt reaches a ceiling when HbA1c reaches
about 8.5% because at this point postprandial hyper-
glycaemia is the main contributor to glycaemic load
(10). Switching to BIAsp 30, comprising rapid-acting
and basal components, was therefore an appropriate
intensiﬁcation insulin choice for these patients.
Results similar to those we show have been
reported by the PRESENT observational study of
BIAsp 30: patients coming from basal insulin ana-
logue therapy achieved a mean HbA1c reduction of
1.6% and those previously treated with human basal
insulins a reduction of 1.4% (both p < 0.0001). Our
ﬁgures were 1.8% and 1.6% respectively, slightly
lower than the mean HbA1c reduction for the global
cohort ()2.3%, n = 52,419) (18). The improvements
in FBG and PPBG in the IMPROVE
TM study were
also comparable with those of the PRESENT study.
The change in FBG was )2.4 mmol⁄l for both basal
insulin groups in the IMPROVE
TM study and )2.8
and )3.7 mmol⁄l for the human and analogue basal
insulin switchers respectively in PRESENT. As
expected, PPBG decreased after breakfast and dinner;
it also decreased after lunch despite no lunchtime
injection in most patients. The lowered PPBG after
breakfast may have also lowered prelunch blood glu-
cose, thus leading to a lower absolute PPBG level at
lunchtime, even if glucose excursions may have been
similar at all time points.
It is very encouraging that almost 40% of patients
in these analyses achieved target HbA1c of < 7.0%
and the majority of these did so without experienc-
ing hypoglycaemia. This compares favourably with
data from a RCT, in which 33% of patients with type
2 diabetes achieved this target using bid BIAsp 30
(approximately one-third of patients were previously
treated with basal insulin) after 26 weeks of therapy
(21). Interestingly, for patients who achieved the
HbA1c target of < 7% without hypoglycaemia, it
seems that an absence of hypoglycaemia, coupled
with a lower baseline HbA1c, enabled these patients
to achieve a much lower ﬁnal HbA1c than the overall
cohort (6.4% vs. 7.4% respectively), with similar
mean doses of BIAsp 30.
Furthermore, the patients in the bid prestudy basal
group did not experience a greater HbA1c reduction
after switching to BIAsp 30 than those in the qd pre-
study basal group; therefore the absolute dose does
not appear to be the key factor in achieving glycae-
mic targets. The current results suggest that dose
titration allows patients to achieve targets, as the
dose increment over the course of the study was very
similar in both groups.
All patients who fail to achieve glycaemic control
with basal insulin, with or without OADs, require
additional treatment measures. Switching insulin
therapy to BIAsp 30, which addresses both basal and
prandial insulin needs, therefore constitutes treat-
ment intensiﬁcation (22). From the results we report
here, we can draw some conclusions about how dose
switching was implemented in real clinical practice.
First, when patients were switched from basal insulin
to BIAsp 30, most were started on a bid regimen;
after 26 weeks, 12% of patients intensiﬁed therapy to
BIAsp 30 tid. Secondly, patients who transferred
from qd basal insulin to BIAsp 30 (mostly to bid)
approximated a 1 : 1 basal insulin transfer and
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lin to BIAsp 30. These data may indicate a stepwise
intensiﬁcation from basal insulin, starting with a
1 : 1 BIAsp 30 qd dose switch, intensifying to BIAsp
30 bid for most patients. Thereafter, a small propor-
tion were switched to BIAsp 30 tid within 6 months.
The 1-2-3 study (9) of BIAsp 30 in patients with
type 2 diabetes supports this progression. Here, 100
patients were started on BIAsp 30 qd and intensiﬁed
to bid and tid at 16-week intervals if target HbA1c
(£ 6.5%) was not achieved. In the 1-2-3 study, the
proportions of patients that reached HbA1c < 7.0%
on qd, bid and tid BIAsp 30 were 41%, 70% and
77% respectively (9).
Observational studies offer the opportunity of
studying large and heterogeneous populations; how-
ever, they also have some limitations. These include
a lack of control groups, potential patient recall bias
and possible variations in clinical practice between
countries. The limitations of the IMPROVE
TM study
have been discussed at length in the article reporting
baseline data (19).
Conclusions
The results of this IMPROVE
TM subgroup analysis
demonstrate that patients with type 2 diabetes inade-
quately controlled on basal insulins may improve
their glycaemic control by intensiﬁcation to BIAsp 30
therapy. Regardless of their prior basal insulin regi-
men, switching to BIAsp 30 – bid in the majority of
cases – enabled many patients in this international
cohort to achieve the HbA1c target without hypo-
glycaemia.
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